SMMT is an oncology biotech with no earnings to date. Bulls are betting on its lead drug receiving U.S. approval, while bears argue that the current valuation is excessive.

Only 17% of shares are floated, with the CEO owning 73%. This very small float means even modest positioning can create significant crowding. Short interest is around 20%.

As the stock fell, short sellers have left positions faster than long investors have, moving the long/short ratio from 0.5 to 0.8, turning SMMT into a battleground stock.

Summit Therapeutics focuses on discovering and developing oncology therapies, with ivonescimab™ (SMT112) as its primary asset, a 2-in-1 drug that attacks the tumor two ways.

Because of the limited float, both long and short exposures are amplified when measured as a percentage of float rather than market cap, increasing volatility and crowding risk.

The squeeze score has declined to approximately 60 as the stock has fallen, but squeeze risk remains elevated if the stock rallies.

The company has not yet achieved profitability and remains in a speculative growth phase, with one drug approved outside the U.S. and multiple additional approvals pending, including in the U.S.

The absence of earnings leaves valuation open to interpretation: bears argue the stock is overvalued, while bulls point to regulatory catalysts as the path to value.

Analyst sentiment remains positive but has softened recently.

While both long and short interest have decreased, short interest has declined more significantly, contributing to the increase in the long/short ratio from 0.5 to 0.80.

The long/short ratio is now 0.8 putting in battleground territory, defined as a ratio close to 1.0. These have a rough equilibrium between longs and shorts.

Want to know more? Access this data in real time using S3’s BLACK APP & BLACK MAP

The information herein (some of which has been obtained from third party sources without verification) is believed by S3 Partners, LLC (“S3 Partners”) to be reliable and accurate. Neither S3 Partners nor any of its affiliates makes any representation as to the accuracy or completeness of the information herein or accepts liability arising from its use. Prior to making any decisions based on the information herein, you should determine, without reliance upon S3 Partners, the economic risks, and merits, as well as the legal, tax, accounting, and investment consequences, of such decisions.